Nicola Gökbuget

Nicola Gökbuget is a leading authority on adult ALL treatment who has coordinated the German Multicenter Study Group for Adult ALL (GMALL) for over 25 years, involving 140+ hospitals across Germany. Her first authorship on the landmark BLAST trial (Blood 2018) established blinatumomab's ability to convert MRD-positive patients to MRD-negative status, fundamentally changing treatment paradigms. As first author of the ELN 2024 ALL guidelines, she shapes global treatment standards. With 382 publications and 20,832 citations, Gökbuget exemplifies the critical role of clinical trial coordinators in translating novel therapies to practice.

Nicola Gökbuget博士是成人ALL治疗的权威专家，25年来一直协调德国成人ALL多中心研究组（GMALL），涉及德国140多家医院。她作为里程碑式BLAST试验（Blood 2018）的第一作者，确立了blinatumomab将MRD阳性患者转化为MRD阴性的能力，从根本上改变了治疗范式。作为ELN 2024 ALL指南的第一作者，她塑造全球治疗标准。凭借382篇出版物和20,832次引用，Gökbuget体现了临床试验协调员在将新疗法转化为实践中的关键作用。